Strongbridge Biopharma plc
SBBP · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Market Cap | $201 | $186 | $136 | $118 |
| - Cash | $64 | $74 | $88 | $82 |
| + Debt | $18 | $18 | $17 | $8 |
| Enterprise Value | $155 | $130 | $66 | $44 |
| Revenue | $10 | $8 | $8 | $8 |
| % Growth | 19.8% | 1.9% | 1.9% | – |
| Gross Profit | $10 | $8 | $8 | $8 |
| % Margin | 95.3% | 95.1% | 94.6% | 94.9% |
| EBITDA | -$11 | -$10 | -$10 | -$1 |
| % Margin | -111.1% | -116.4% | -123.1% | -16.9% |
| Net Income | -$13 | -$12 | -$12 | -$3 |
| % Margin | -131.9% | -140.9% | -145.2% | -39.1% |
| EPS Diluted | -0.19 | -0.18 | -0.21 | -0.055 |
| % Growth | -5.6% | 14.3% | -281.8% | – |
| Operating Cash Flow | -$10 | -$13 | -$5 | -$6 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$10 | -$13 | -$5 | -$6 |